Anagrelide: What Was New in 2004 and 2005?

ABSTRACT

Anagrelide is an established platelet-reducing drug. Although there are gaps in the understanding of its mechanism of action, two randomized comparisons with other drugs used for therapy of patients with essential thrombocythemia (ET) have been performed. Recent progress has been made in this field with the development of better determination techniques, with the characterization of metabolites, and with studies of their mechanism of action on megakaryocytes and platelets. More data are now available from various noncomparative clinical trials on its clinical efficacy and safety. Only few investigations are available that document its long-term effects. Although the drug should not be used during pregnancy, there are a few studies that report that pregnant women have taken this drug without harm to the newborn. Studies have also investigated the effects of anagrelide on platelets, indicating that platelet function is as important as platelet counts in ET. Preliminary analyses of the mechanism of action of anagrelide have revealed that the drug interferes with the signal transduction of the thrombopoietin receptor. Results of the first phase III trial (PT1) that compared anagrelide/aspirin with hydroxyurea/aspirin have sparked an intense discussion, given that the combination of anagrelide and aspirin causes more bleeding complications in the gastrointestinal tract. It has been speculated that the higher number of transient ischemic attacks in this study arm is not caused by thrombotic events but by small bleedings that would be responsible for transient hemorrhagic attacks. More insights are expected from the recently completed ANAHYDRET trial that compared monotherapy with hydroxyurea and anagrelide.

KEYWORDS

Anagrelide - mechanism of action - clinical efficacy - adverse effects - transient ischemic attacks - PT1 - anahydret

REFERENCES

• 1 Petrides P E. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythemia.  Expert Opin Pharmacother. 2004;  5 1781-1798
• 2 Zhu Z, Gonthier R, Neirinck L. High-performance liquid chromatography-mass spectrometry method for determination of anagrelide in human plasma.  J Chromatogr B Analyt Technol Biomed Life Sci. 2005;  822 238-243
• 3 Wang G, Franklin R, Hong Y, Erusalimsky J D. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.  Br J Pharmacol. 2005;  146 324-332
• 4 Steurer M, Gastl G, Jedrzejczak W W et al.. Anagrelide for thrombocytosis in myeloproliferative disorders.  Cancer. 2004;  101 2239-2246
• 5 Mazur G, Wróbel T, Podolak-Dawidziak M et al.. Anagrelide in the treatment of thrombocythaemia essentialis.  Pol Arch Med Wewn. 2004;  112 1445-1450
• 6 Silver R T. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.  Leukemia. 2005;  19 39-43
• 7 Mazzucconi M G, Redi R, Bernasconi S et al.. A long-term study of young patients with essential thrombocythemia treated with anagrelide.  Haematologica. 2004;  89 1306-1313
• 8 Siegel F, Petrides P E. Efficacy and safety of anagrelide in 30 long-term (up 14.8 years) users.  Onkologie. 2005;  28(suppl 3) 81-82
• 9 Fruchtman S M, Petitt R M, Gilbert H S, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.  Leuk Res. 2005;  29 481-491
• 10 Doubek M, Brychtova Y, Doubek R, Janku P, Mayer J. Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia.  Ann Hematol. 2004;  83 726-727
• 11 Alkindi S, Dennison D, Pathare A. Successful outcome with anagrelide in pregnancy.  Ann Hematol. 2005;  84 758-759
• 12 Engel P J, Johnson H, Baughman R P, Richards A I. High-output heart failure associated with anagrelide therapy for essential thrombocytosis.  Ann Intern Med. 2005;  143 311-313
• 13 Jurgens D J, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.  Haematologica. 2004;  89 1394-1395
• 14 Swords R, Fay M, O'Donnell R, Murphy P T. Anagrelide-induced visual hallucinations in a patient with essential thrombocythemia.  Eur J Haematol. 2004;  73 223-224
• 15 Rodwell GEJ, Troxell M L, Lafayette M A. Renal tubular injury associated with anagrelide use.  Nephrol Dial Transplant. 2005;  98 998-990
• 16 Spencer E M, Lawrence D S. “Double hit” from streptococcal pneumonia and hypersensitivity pneumonitis associated with anagrelide.  Clin Lab Haematol.. 2006;  28 63-65
• 17 Lev P R, Salim J P, Kornblihtt L I et al.. PDGF-A, PDGF-B, TGFβ1 and bFGF mRNA Levels in patients with essential thrombocythaemia treated with anagrelide.  Am J Hematol. 2005;  78 155-157
• 18 Cacciola R R, Di Francesco E, Giustolisi R, Cacciola E. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythaemia.  Br J Haematol. 2004;  126 885-886
• 19 Cacciola R R, Cipolla A, Di Francesco E, Giustolisi R, Cacciola E. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.  Am J Hematol. 2005;  80 81-83
• 20 Thiele J, Kvasnicka H M, Ollig S, Schmitt-Gräff A. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea.  Histol Histopathol. 2005;  20 1071-1076
• 21 McCarty J M, Melone P D, Simanis J P, Kanamori D, Dessypris E N, Warshamana-Greene G S. A preliminary investigation into the action of anagrelide: thrombopoietin-c-mpl receptor interactions.  Exp Hematol. 2006;  34 87-96
• 22 Harrison C N, Campbell P J, Buck G et al.. Hydroxyurea plus aspirin compared with hydroxyurea plus aspirin in high risk essential thrombocythemia.  N Engl J Med. 2005;  353 33-45
• 23 Petrides P E. The anagrelide-hydroxyurea controversy in Europe. Paper presented at: The Third European MPD Workshop on Clinical, Pathological and Molecular Features of Ph-Chromosome Negative Myeloproliferative Disorders. March 31-April 2, 2006 Rotterdam, The Netherlands;
• 24 Campbell P J, Scott L M, Buck G et al.. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2V617F mutation status: a prospective study.  Lancet. 2005;  366 1945-1953
• 25 Anahydret Study Group. Interim Analysis as of June 24, 2005. AOP 03-007-Anahydret Study.